Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
23.34B
Market cap23.34B
Price-Earnings ratio
16.53
Price-Earnings ratio16.53
Dividend yield
Dividend yield
Average volume
2.32M
Average volume2.32M
High today
$118.69
High today$118.69
Low today
$112.99
Low today$112.99
Open price
$114.18
Open price$114.18
Volume
2.63M
Volume2.63M
52 Week high
$118.69
52 Week high$118.69
52 Week low
$66.85
52 Week low$66.85

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $116.77. The company's market cap stands at 23.34B, with a P/E ratio of 16.53.

During the trading session on 2026-07-03, Incyte(INCY) shares reached a daily high of $118.69 and a low of $112.99. At a current price of $116.77, the stock is +3.3% higher than the low and still -1.6% under the high.

Trading activity shows a volume of 2.63M, compared to an average daily volume of 2.32M.

The stock's 52-week range extends from a low of $66.85 to a high of $118.69.

The stock's 52-week range extends from a low of $66.85 to a high of $118.69.

INCY News

Simply Wall St 1d
How Investors May Respond To Incyte EMA Backing Opzelura For Moderate Atopic Dermatitis

In late June 2026, Incyte announced that the European Medicines Agency’s CHMP issued a positive opinion recommending approval of Opzelura (ruxolitinib) cream fo...

How Investors May Respond To Incyte EMA Backing Opzelura For Moderate Atopic Dermatitis
Simply Wall St 2d
Incyte Stock May Be 33% Overvalued After Opzelura EU Win

Incyte stock has delivered a strong 82.6% return over the past three years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiple...

Incyte Stock May Be 33% Overvalued After Opzelura EU Win
MarketWatch 3d
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

...

Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

Analyst ratings

55%

of 29 ratings
Buy
41.4%
Hold
55.2%
Sell
3.4%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.